drugset / Trial / NCT04438096
Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if CVI-LM001 is effective and safe versus placebo in drug-naive subjects with elevated LDL cholesterol. There will be 4 groups receiving 100mg, 200mg, 300 mg and placebo treatment for 12 weeks respectively.
Timeline
- Start
- 2020-07-15
- Primary completion
- 2021-12-15
- Completion
- 2022-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVI-LM001 | Unknown | 100 mg | Oral |
| Subject | CVI-LM001 | Unknown | 200 mg | Oral |
| Subject | CVI-LM001 | Unknown | 300 mg | Oral |